Primary plasma cell leukemia and autologous stem cell transplantation

Haematologica

Volumn 95, Issue 5, 2010, Pages 804-809

  Drake, Mary B ^a   Iacobelli, Simona ^b   van Biezen, Anja ^b   Morris, Curly ^a   Apperley, Jane F ^c   Niederwieser, Dietger ^d   Björkstrand, Bo ^e   Gahrton, Gösta ^e  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Autotransplantation; Overall survival; Plasma cell leukemia

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE; HEMOGLOBIN;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGISTRY; CONTROLLED STUDY; EUROPE; FEMALE; HEALTH STATUS; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; WHOLE BODY RADIATION;

FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, PLASMA CELL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 77952312712     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.013334     Document Type: Article

References (28)

1. Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukemia. Br J Haematol. 1994;88(44):754-9.
2. García-Sanz R, Orfão A, González M, Tabernero MD, Bladé J, Moro MJ, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy and cytogenetic characteristics. Blood. 1999;93(3): 1032-7.
3. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med. 1974;133(5):813-8.
4. Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terré C, Lafage-Pochitaloff M, et al. Cytogenetic, interphase and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood. 2001;97(3):822-5.
5. Smadja NV, Bastard C, Brigadeau C. Primary plasma cell leukemia and multiple myeloma: one or two diseases according to the methodology. Blood. 1999;94(10):3607-9.
6. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5):1115-23.
7. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med. 1987;83(6):1062-8.
8. Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol/Oncol Clin North Am. 1999;13(6):1259-72.
9. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50(1):29-40.
10. Pellat-Deceunynck C, Barillé S, Jego G, Puthier D, Robillard N, Pineau D, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998, 12(12):1977-82.
11. McElwain TJ, Powles RL. High-dose intra-venous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2(8354):822-4.
12. Panizo C, Rifón J, Rodríguez-Wilhelmi P, Cuesta B, Rocha E. Long-term survival in primary plasma cell leukemia after therapy with VAD, autologous blood stem cell transplantation and interferon-alpha. Acta Haematol. 1999;101(4):193-6.
13. Hovenga S, de Wolf JT, Klip H, Vellenga E. Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature. Bone Marrow Transplant. 1997;20(10):901-4.
14. Sajeva MR, Greco MM, Cascavilla N, D'Arena G, Scalzulli P, Melillo L, et al. Effective autologous peripheral blood stem cell transplantation in plasma cell leukemia followed by T-large granular lymphocyte expansion: a case report. Bone Marrow Transplant. 1996;18(1):225-7.
15. Mak YK, Chan CH, Chen YT, Lau SM, So CC, Wong KF. Consolidation therapy with autologous blood stem cell transplantation in a patient with primary plasma cell leukaemia. Clin Lab Haematol. 2003;25(1): 55-8.
16. Sica S, Chiusolo P, Salutari P, Piccirillo N, Laurenti L, Ortu La Barbera E, et al. Long-lasting complete remission in plasma cell leukemia after aggressive chemotherapy and CD34-selected autologous peripheral cell transplant: molecular follow-up of minimal residual disease. Bone Marrow Transplant. 1998;22(8):823-5.
17. Yeh KH, Lin MT, Tang JL. Long-term disease free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third-complementarity-determining region-specific probes. Br J Haematol. 1995; 89(4):914-6.
18. Corradini P, Ladetto M, Voena C, Palumbo A, Inghirami G, Knowles DM, et al. Mutational activation of Nand K-ras oncogenes in plasma cell dyscrasias. Blood. 1993;81(10):2708-13.
19. Portier M, Molès JP, Mazars GR, Jeanteur P, Bataille R, Klein B, Theillet C. p53 and RAS gene mutations in multiple myeloma. Oncogene. 1992;7(12):2539-43.
20. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. P53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood. 1993; 81(1):128-35.
21. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93(1):55-65.
22. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol. 1998;102(2):495-502.
23. Björkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2001;27(5):511-5.
24. Petrucci MT, Martini V, Levi A, Cristiano Gallucci, Giovanna Palumbo, Patrizia Del Bianco, et al. Thalidomide does not modify the prognosis of plasma cell leukemia patients. Experience of a single centre. Leuk Lymphoma. 2007;48(1):180-2.
25. Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995;86(2):685-91.
26. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991;78(5):1198-204.
27. Finnegan DP, Kettle P, Drake M, Matthews C, Alexander HD, Popat R, et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma. 2006; 47(8):1670-3.
28. Jaskiewicz AD, Herrington JD, Wong L. Tumour lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy. 2005;25(12):1820-5.